What is the price of tepotinib in 2025? Interpretation of medical insurance reimbursement policies

Tepotinib has been officially launched in China and has been included in the national medical insurance directory. It is targeted at adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. After being included in medical insurance, the reimbursement ratio of such high-priced targeted drugs has significantly increased, effectively easing the financial burden on patients. The current price of domestic original research version of tepotinib is still relatively high, about 30,000 yuan per box. The specific price fluctuates slightly due to regional medical insurance policies.

After medical insurance reimbursement, the actual out-of-pocket price may be reduced to about 15,000 yuan. The specifics need to refer to factors such as the local medical insurance pooling ratio and the patient’s identity (such as whether it is covered by critical illness insurance or urban employee medical insurance). Reimbursement usually requires the patient to provide a genetic test report proving that the MET mutation is positive, and at the same time, a prescription must be issued at a designated medical institution and the medical insurance registration must be completed.

At the same time, with the expansion of the overseas generic drug market, the Laos market has become an important source of tepotinib generic drugs. In 2025, companies such as Luscius and Daibear in Laos have launched generic versions of tepotinib on a large scale. The price is about 6,000 yuan per box, which has more economic advantages than domestic original drugs. Most of these generic drugs use the same active ingredients and specifications as the original drugs and meet the equivalence standards for generic drugs recommended by the WHO. However, because they have not been officially approved by China's NMPA, there is still a gray area in terms of legal and compliant use, so you need to be extra cautious when purchasing. At present, some patients obtain generic drugs through overseas pharmaciesdrug purchase platforms to reduce the pressure of long-term medication. However, priority should be given to assessing the formality of their sources and the authenticity of the drugs to avoid affecting the safety of treatment.

Generally speaking, although the price of tepotinib is gradually becoming more rational, it still belongs to the category of high-priced targeted drugs. The intervention of medical insurance policies has significantly improved its accessibility, which is especially significant for patients with mid-to-late stage lung cancer who are under great financial pressure.

Reference materials:https://www.tepotinib.com/